A Phase 1 interventional study of SGN-CD70A in Renal Cell Carcinoma, Mantle-Cell Lymphoma and Diffuse, Large B-Cell, Lymphoma, sponsored by Seagen Inc.. Completed at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-19.
Sponsored by Seagen Inc. (part of Pfizer) · Phase 1, Interventional, and Treatment
This study will examine the safety profile of SGN-CD70A. The study will test increasing doses of SGN-CD70A given every 3 weeks (or an alternate dosing schedule up to every 6 weeks) to small groups of patients. The goal is to find the highest dose of SGN-CD70A that can be given to patients without causing unacceptable side effects. The pharmacokinetics and antitumor activity of SGN-CD70A will also be evaluated.
1,992 studies on the registry are indexed under Carcinoma, Renal Cell; 387 are open to participants now.
This study's enrollment of 38 is close to the median of 42 across 1,501 interventional studies indexed under Carcinoma, Renal Cell.
Browse Carcinoma, Renal Cell studies →Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
First submitted before Seagen Inc. became part of Pfizer.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: SGN-CD70A
Given intravenously every 3 weeks (or an alternate dosing schedule up to every 6 weeks)
Incidence of adverse events
Time frame: Through 1 month following last dose
Incidence of laboratory abnormalities
Time frame: Through 1 month following last dose
Blood concentrations of SGN-CD70A and metabolites
Time frame: Through 3 to 6 weeks after dosing
Incidence of antitherapeutic antibodies
Time frame: Through 1 month following last dose
Objective response rate
Time frame: Through 1 month following last dose
Progression-free survival
Time frame: Approximately 3 years
Duration of response
Time frame: Approximately 3 years
Exploratory biomarkers of pharmacodynamic effects due to SGN-CD70A
Time frame: Through 1 month following last dose
Ran from Aug 2014 to primary completion in Feb 2017, 30 months.
Of 121 industry-sponsored phase 1 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 65. This study's 30 months is below that.
Counting every sponsor, half of 200 studies reached it within 51 months; a quarter within 32 and three quarters within 74.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.